Big LDL drops with PCSK9 inhibition in grouped phase 2 studies

The analysis combined four phase 2 studies and showed that AMG145, an investigational human monoclonal antibody that inhibits PCSK9, reduced LDL cholesterol by as much as 64%.
Source: theHeart.org - Category: Cardiology Source Type: news